Head and Neck Cancer Clinical Trial
Official title:
GCC1043: Magnetic Resonance Imaging for Evaluating Tumor and Node Response and Normal Tissue Function to Concurrent Chemotherapy and Radiation Therapy in Head and Neck Cancer
The investigators' goal is to incorporate advanced imaging information into the treatment
planning process and assess response in tumor, nodes and non-cancerous tissues in head and
neck cancer patients during and after concurrent chemotherapy and radiation therapy (chemoRT)
via biophysical, biochemical and vascular imaging using magnetic resonance imaging (MRI). The
investigators will recruit 30 patients with locally advanced head and neck cancer into the
study. All patients will obtain an advanced MRI study at three time points: 1) before the
start of chemoRT, 2) 4 weeks following the start of chemoRT, and 3) 3-4 months following
completion of chemoRT. MRI scans will include a) T1, T2 and T2* imaging, b) vascular images
using dynamic contrast enhanced (DCE) imaging, c) biophysical microstructure images using
diffusion-weighted imaging, and d) biochemical images using MR spectroscopic imaging. The
subject's response (tumor, nodes and salivary and mucosal tissues) will be evaluated using
clinical outcomes. Correlations will be generated between the parameters obtained from MR
images and from clinical response assessments.
The purpose of this study is to assess whether advanced MR imaging techniques can be used to
determine tumor and node response (i) four weeks following initiation of concurrent chemoRT
and (ii) after completion of chemoRT in head and neck cancer, and to assess whether advanced
MR imaging techniques can be used to predict early at-risk organ function (salivary gland and
mucosal injury) as measured by salivary flow and oral mucositis to chemoradiation therapy (i)
four weeks following initiation of concurrent chemoRT and (ii) after completion of chemoRT in
head and neck cancer.
MRI scans will be performed at three time points. The time points will be 1-2 weeks prior to
the start of treatment, between 4 and 5 weeks after the start of treatment (i.e., after the
20th radiation treatment fraction and before the start of the 25th radiation treatment
fraction), and 3-4 months after the completion of chemoRT. Scans acquired at the first and
third time points will be clinically indicated (except for the spectroscopy scan) and ordered
by the treating physician. The scan session corresponding to the second time point will be
for research purposes. The investigators chose 4-5 weeks as the time point for predicting
early response to chemoRT for the following reason. In a 7-week treatment regimen, an
indicator tested at > 5 weeks would have limited predictive utility in the consideration of
an alternative therapy, i.e., surgical intervention. However, an indicator measured at <= 5
weeks (i.e., with enough time remaining to the end of therapy) might potentially inform the
therapeutic course of action in future studies. If this pilot study demonstrates utility of
advanced MR imaging techniques identified at 4-5 weeks, future studies could focus on the
optimal timing for assessment of early response. The time point of 3-4 months is selected for
assessing post-therapy response because it coincides with the clinical follow-up schedule (at
which an image-based assessment of response is performed via a clinical exam and/or PET
imaging) that determines the standard of care response.
T1, T2, and T2* MRI scans will be performed to delineate head and neck tissues. DCE MRI scans
will provide quantitative assessment of contrast uptake in tissues and tissue vasculature
both during and at follow-up after completion of chemoRT. Contrast on images will be provided
by a gadolinium-based contrast agent (GBCA). GBCA is FDA-approved and is routinely used in
dynamic contrast-enhanced MRI scans. Further, contrast enhanced MRI is typically obtained on
all cancer patients including head and neck cancer as part of routine clinical care.
Diffusion MRI scans will provide information on the diffusion of water molecules in tumor,
nodes and other head and neck tissues. MR spectroscopy scans will provide information on
tissue metabolites. All scans acquired prior to the start of chemoRT will provide baseline
maps against which functional maps acquired during and after completion of chemoRT will be
compared to determine the relative change in anatomical, biophysical and biochemical
parameters.
Image anatomy and parameter maps will be correlated with dose maps derived from CT images by
registering (fusing) MRI images with CT images acquired as part of standard of care and used
for treatment planning of the subject's radiation treatment.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05808920 -
The RESCUE Study: Survival and Functional Outcomes Following Salvage Surgery for RESidual or reCurrent sqUamous cEll Carcinoma of the Head and Neck
|
||
Completed |
NCT02526017 -
Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
|
Phase 1 | |
Active, not recruiting |
NCT05060432 -
Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT03997643 -
Preservation of Swallowing in Respected Oral Cavity Squamous Cell Carcinoma: Examining Radiation Volume Effects (PRESERVE): A Randomized Trial
|
Phase 2 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT04700475 -
Effect of Low Level Laser Therapy on Prevention of Radiotherapy Induced Xerostomia in Cancer Patients.
|
N/A | |
Withdrawn |
NCT04058145 -
AMD3100 Plus Pembrolizumab in Immune Checkpoint Blockade Refractory Head and Neck Squamous Cell Carcinoma
|
Phase 2 | |
Completed |
NCT02572869 -
Functional and Aesthetic Outcomes After Mandible Reconstruction With Fibula Osteomyocutaneous Free Flaps
|
||
Active, not recruiting |
NCT04474470 -
A Study to Evaluate NT219 Alone and in Combination With ERBITUX® (Cetuximab) in Adults With Advanced Solid Tumors and Head and Neck Cancer
|
Phase 1/Phase 2 | |
Withdrawn |
NCT05073809 -
Photoacoustic Imaging of Head and Neck Tumours
|
||
Active, not recruiting |
NCT04383210 -
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
|
Phase 2 | |
Active, not recruiting |
NCT03651570 -
Randomized Controlled Trial of a E-intervention to Help Patients Newly Diagnosed With Cancer Cope Better: Pilot Study
|
N/A | |
Recruiting |
NCT04930432 -
Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT06016699 -
Immunological Function After Radiation With Either Proton or Photon Therapy
|
||
Terminated |
NCT03843554 -
Commensal Oral Microbiota in Head and Neck Cancer
|
N/A | |
Recruiting |
NCT05915572 -
Mulligan Technique on Shoulder Dysfunction
|
N/A | |
Completed |
NCT05897983 -
Tens and Rocabado Exercises on TMJ Dysfunction
|
N/A | |
Not yet recruiting |
NCT06289049 -
Heavy Strength Training in Head and Neck Cancer Survivors
|
Phase 2 | |
Withdrawn |
NCT05263648 -
Virtual Reality Software to Reduce Stress in Cancer Patients
|
N/A | |
Withdrawn |
NCT03238638 -
A Study of Epacadostat + Pembrolizumab in Head and Neck Cancer Patients, Who Failed Prior PD-1/PD-L1 Therapy
|
Phase 2 |